MedPath

TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. logo
🇹🇼Taiwan
Ownership
Subsidiary
Established
2010-01-01
Employees
344
Market Cap
-
Website
http://www.twipharma.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

34

FDA:34

Drug Approvals

Diltiazem Hydrochloride

Approval Date
Sep 15, 2025
FDA

Terbutaline Sulfate

Approval Date
Aug 27, 2025
FDA

Fluoxetine HCl

Approval Date
Dec 29, 2023
FDA

bupropion hydrochloride

Approval Date
Dec 27, 2023
FDA

Forfivo

Approval Date
Dec 27, 2023
FDA

Topiramate

Approval Date
Dec 5, 2023
FDA

Diltiazem Hydrochloride

Approval Date
Nov 8, 2023
FDA

Potassium Chloride

Approval Date
Nov 8, 2023
FDA

testosterone

Approval Date
Nov 8, 2023
FDA

Dicyclomine Hydrochloride

Approval Date
Nov 8, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.